Monday, 12 April 2021

NephroPlus appoints Dr Om Prakash Manchanda as Independent Director

12 March 2021 | News

Dr Manchanda is the Managing Director of Dr Lal PathLabs



NephroPlus has added another feather to the cap with the addition of Dr Om Prakash Manchanda into the Board of Directors as an Independent Director. This induction will further help NephroPlus in its scale-up journey as it expands in domestic and international markets.

Dr Manchanda is the Managing Director of Dr Lal PathLabs. With their strategic vision and operational abilities, Dr Manchanda has helped transform Dr Lal PathLabs into its current network of over 200 labs, more than 2,500 patient service centres, and close to 6,500 sample pick-up-points.

Before joining Dr Lal PathLabs in 2005, Dr Manchanda led the International & Innovation group of the Consumer Healthcare Division at Ranbaxy. He  has also worked for Monsanto as the head of Sales and Marketing, where his team successfully launched the company's first ever biotech product Bt-Cotton. Earlier, during his tenure with Hindustan Unilever for about 10 years, he received in-depth exposure in consumer product sales, distribution and marketing. An MBA from the Indian Institute of Management, Ahmedabad, Dr Manchanda is also a Doctor in Veterinary Sciences from HAU, Hisar. He is also an alumnus of Harvard Business School and recipient of several awards including Healthcare Personality of the Year Award in 2020 by FICCI, and EY Entrepreneur of the Year Award in 2019 under Healthcare category.

Speaking on this occasion, Vikram Vuppala, Founder and CEO, NephroPlus said, “We are delighted to welcome Dr Om Prakash Manchanda to the Board of Directors at NephroPlus. We are sure he will add a strong independent voice in our Board discussions related to our future expansion plans in India and the overseas markets. I am personally looking forward to working with him as we embark on our next phase of growth.”

Speaking on the new role Dr Manchanda said, “I have been tracking NephroPlus for several years now and have watched the company grow in India and recently in the overseas markets as well. What excites me the most about NephroPlus is its patient centricity, which is very crucial in healthcare systems. The current dominant leadership position in India and the thoughtful approach with which the company is pursuing international markets are quite compelling success factors. I look forward to supporting NephroPlus in the next phase of its scale-up journey in India and beyond.”


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls